Additionally, to date, several cases of IPA in cancer patients treated with the new anti-cancer therapeutics bevacizumab, a VEGF inhibitor, or pazopanib, a VEGF receptor inhibitor, have been reported (69, 70). This evidence concerns the gene VEGFA and Ito hypomelanosis.